Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Biogen Releases Clinical Trial Data for Alzheimer’s Drug at CTAD Meeting

XTALKS VITALS NEWS

Clinical Trial

The interim results suggest that slowly increasing the dose of aducanumab could help reduce the risk of brain swelling, compared to administration of a consistently high dose throughout the trial period.

Share this!

December 13, 2016 | by Sarah Hand, M.Sc.

Biotech company, Biogen, presented more positive data for its experimental Alzheimer’s disease drug, aducanumab, at the 9th Clinical Trials on Alzheimer's Disease (CTAD) meeting. The drug is designed to clear beta amyloid plaques from the brains of people suffering from the neurodegenerative disease, and is currently being assessed in a Phase Ib clinical trial.

The interim results suggest that slowly increasing the dose of aducanumab could help reduce the risk of brain swelling, compared to administration of a consistently high dose throughout the trial period. The study – which involved 31 patients with early-stage Alzheimer’s – found that the drug was effective at reducing amyloid plaques in the brains of patients in the titration arm, compared to the placebo.



“The data at CTAD support the positive results we have seen in our Phase 1b study of aducanumab, and they provide insight into the observed effects in patients treated for up to two years,” said Samantha Budd Haeberlein, vice president, clinical development at Biogen. “We are committed to advancing our global Phase 3 program for aducanumab as well as the scientific understanding of Alzheimer’s disease so we can help identify a treatment for the many people affected by this terrible disease.”

According to Biogen, 35 percent of patients in the titration group experienced changes in fluid volume in the brain, compared to 55 percent of those who were given a fixed dose of aducanumab. In addition to this Phase I clinical trial, the Alzheimer’s drug is also being tested in two Phase III studies involving escalating dosing.

Patients enrolled in this Phase I trial also saw a reduction in the rate of mental decline after 12 months of treatment. These patients were characterized as having mild or prodromal Alzheimer’s disease, potentially making them more receptive to treatment compared to people with more advanced forms of the disease.

While other pharmaceutical companies – most notably, Eli Lilly – have tried to develop drugs targeting beta amyloid plaques in the brain, these drugs have largely been unsuccessful. Alzheimer’s researchers have stressed the importance of diagnosing the disease early, before the formation of significant brain-damaging plaques, so that patients have the best chance of benefitting from investigational new treatments.


Keywords: Clinical Trial, Alzheimer's Disease, Drug Development


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
Exclusion Criteria for Clinical Trials Poses Major Barrier to Patient Enrollment

August 17, 2017 - UT Southwestern researchers say that clinical investigators continue to increase the number of exclusion criteria, preventing more patients from participating in clinical trials.

Featured In: Clinical Trials News


Targeting Cellular Nitrogen Metabolism Could Offer a New Treatment for Pancreatic Cancer

August 17, 2017 - An enzyme involved in regulating the amount of nitrogen in the cell could be a new drug target for pancreatic cancer, according to researchers from Boston Children's Hospital and the Broad Institute of MIT and Harvard.

Featured In: Life Science News


Regeneron’s Drug for Respiratory Syncytial Virus Fails in Phase III Clinical Trial

August 16, 2017 - Biotechnology company Regeneron has announced it will not continue development of its antibody drug, suptavumab, after a failure in a Phase III clinical trial.

Featured In: Clinical Trials News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

One Patient’s Perspective on Clinical Trials

REGISTER FOR THESE WEBINARS

Planning and Conducting Trials of the Latest Immunotherapies


ISO 13485:2016 for Medical Device Manufacturers: Ensuring a Smooth Transition through Effective Preparation


Medical Devices: Reviewing Regulatory Changes in the US and EU


Moving Beyond Regulatory and Performance Metrics in Starting Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.